Date: 2016-07-27
Type of information: Nomination
Compound:
Company: Neon Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 27, 2016, Neon Therapeutics announced the appointment of Hugh O’Dowd to chief executive officer.
Mr. O’Dowd succeeds interim chief executive officer Cary Pfeffer, M.D., a partner at Third Rock Ventures, who is assuming the position of chairman of the company’s board
of directors.
Mr. O’Dowd brings deep experience to Neon Therapeutics in pharmaceutical leadership, moving important oncology therapies from clinical development through commercialization. He joins Neon Therapeutics from Novartis, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head
of global strategy of Novartis Oncology. In this role, he was responsible for global commercialization for the oncology portfolio, including Global Brand Leadership, Health Economics & Pricing, Early Phase Commercial Development, Strategic Capabilities, Business Development & Licensing and Global Sales Excellence.
Financial terms:
Latest news:
Is general: Yes
